JW (Cayman) Therapeutics Co. Ltd
JWCTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $106,346 | $71,403 | $86,815 | $86,116 |
| % Growth | 48.9% | -17.8% | 0.8% | – |
| Cost of Goods Sold | $41,229 | $37,832 | $43,070 | $42,710 |
| Gross Profit | $65,117 | $33,571 | $43,745 | $43,406 |
| % Margin | 61.2% | 47% | 50.4% | 50.4% |
| R&D Expenses | $92,041 | $131,981 | $151,008 | $197,085 |
| G&A Expenses | $32,190 | $60,835 | $59,233 | $61,354 |
| SG&A Expenses | $90,684 | $125,076 | $135,405 | $114,382 |
| Sales & Mktg Exp. | $58,494 | $64,241 | $76,172 | $53,028 |
| Other Operating Expenses | $0 | -$470,999 | $4,845 | $131,626 |
| Operating Expenses | $182,725 | -$213,942 | $291,258 | $443,093 |
| Operating Income | -$117,608 | $247,513 | -$247,513 | -$399,687 |
| % Margin | -110.6% | 346.6% | -285.1% | -464.1% |
| Other Income/Exp. Net | -$149,657 | -$597,870 | $7,246 | $12,106 |
| Pre-Tax Income | -$267,265 | -$350,357 | -$240,267 | -$387,581 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$267,265 | -$350,357 | -$240,267 | -$387,581 |
| % Margin | -251.3% | -490.7% | -276.8% | -450.1% |
| EPS | -0.64 | -0.84 | -0.58 | -0.94 |
| % Growth | 23.8% | -44.8% | 38.3% | – |
| EPS Diluted | -0.64 | -0.84 | -0.58 | -0.94 |
| Weighted Avg Shares Out | 415,633 | 414,185 | 413,083 | 411,933 |
| Weighted Avg Shares Out Dil | 415,632 | 414,185 | 413,083 | 411,933 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,177 | $8,965 | $0 | $12,106 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $33,974 | $32,353 | $35,594 | $36,138 |
| EBITDA | -$80,067 | -$186,164 | -$204,921 | -$225,477 |
| % Margin | -75.3% | -260.7% | -236% | -261.8% |